Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response-Reference-Cited by-同舟云学术

Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response

Published:2022-05 Issue: Volume:79 Page:104010
ISSN:2352-3964
Container-title:eBioMedicine
language:en
Short-container-title:eBioMedicine

Author:

Scirocchi Fabio^ORCID,Scagnoli Simone,Botticelli Andrea^ORCID,Di Filippo Alessandra^ORCID,Napoletano Chiara,Zizzari Ilaria Grazia,Strigari Lidia,Tomao Silverio,Cortesi Enrico,Rughetti Aurelia,Marchetti Paolo,Nuti Marianna^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference53 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going;Schettini;Cancer Treat Rev,2016

3. Hallmarks of cancer: the next generation Elsevier enhanced reader;Hanahan;Cell,2011

4. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1;Harbour;Cell,1999

5. Overall survival of CDK4/6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis;Schettini;J Natl Cancer Inst,2020

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2− breast cancer;International Immunopharmacology;2024-12

2. Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib;Critical Reviews in Oncology/Hematology;2024-10

3. CD25+FOXP3+CD45RA− regulatory T-cell infiltration as a prognostic biomarker for endometrial carcinoma;BMC Cancer;2024-09-04

4. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

5. Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09